According to him, the vaccine is currently in preclinical studies.
“We hope to receive the first results at the end of the year and then start clinical trials,” the minister told the agency within the framework of the St. Petersburg International Economic Forum.
Murashko noted that several scientific teams work together on the vaccine, named after the Research Center for Epidemiology and Microbiology. NF Gamaleya, Moscow Cancer Research Institute named after. PA Herzen and the National Medical Research Center for Oncology that bears his name. NN Blokhina.
The development of the drug is financed by the state within the framework of state allocations, added the head of the Russian Ministry of Health.
It was previously reported that the FAS agreed on the price of the Russian oncology drug Crizotinib-Promomed, the first domestic generic with the active substance Crizotinib for the treatment of non-small cell lung cancer. According to the department, the drug will cost 40% less than its foreign counterpart.
